Brief: Valerio Therapeutics Signs Development Collaboration With Abivax
BRIEF-Valerio Therapeutics Signs Development Collaboration With Abivax July 16 (Reuters) - Valerio Therapeutics SA ALVIO.PA:
VALERIO AND ABIVAX ENTER INTO A BINDING TERM-SHEET FOR AN EXCLUSIVE GLOBAL RESEARCH AND DEVELOPMENT COLLABORATION
WILL RECEIVE AN UPFRONT PAYMENT UP TO AROUND €2.4 MILLION AND WOULD BE ELIGIBLE TO RECEIVE DEVELOPMENT AND COMMERCIAL MILESTONE PAYMENTS, AS WELL AS ROYALTIES ON NET SALES AND SUBLICENSING REVENUES
FINAL TERMS REMAIN SUBJECT TO SIGNING OF DEFINITIVE CO-OWNERSHIP AND LICENSE AGREEMENT
VALERIO AND ABIVAX WILL WORK TOGETHER TO IDENTIFY, DESIGN AND EVALUATE NEXT-GENERATION THERAPEUTIC CANDIDATES FOR IMMUNE-MEDIATED INFLAMMATORY DISEASES
COLLABORATION WILL INCLUDE GENERATION, MANUFACTURING AND PRECLINICAL EVALUATION OF RESEARCH CANDIDATES
Source text: ID:nBw5pCmJDa
Further company coverage: ALVIO.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Valerio Therapeutics SA
See all newsBrief: Valerio Therapeutics To Buy Etherna Immunotherapies For €30 Mln
Brief: Valerio Therapeutics Signs Development Collaboration With Abivax
Brief: Valerio Therapeutics Enters Into Collaboration & Exclusive License With Seed-Stage Biotech Co
Brief: Onxeo Changes Its Name And Becomes Valerio Therapeutics
Brief: Onxeo H1 Net Loss Widens To EUR 11.5 Mln